U.S. FDA GRANTS BIRCHBIOMED ORPHAN DRUG DESIGNATION FOR FS2 IN THE TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS

CNW/ - BirchBioMed Inc., a leading clinical stage biopharmaceutical company, expert in the development of products for ...
PharmTech

BirchBioMed’s Idiopathic Pulmonary Fibrosis Treatment Receives Orphan Drug Designation

FDA has granted orphan drug designation to FS2 (kynurenic acid) for the investigational treatment of idiopathic pulmonary ...
The American Journal of Managed Care

Report Highlights Advancements in 2024 Idiopathic Pulmonary Fibrosis Pipeline

More than 100 therapies for idiopathic pulmonary fibrosis are being developed across the globe. IPF is a chronic and progressive lung disease that affects the tissue surrounding the air sacs in the ...
Business Insider

Global Idiopathic Pulmonary Fibrosis (IPF) Pipeline Analysis Report 2017: 97 Product Candidates - 1 in Phase III, 15 in Phase II, 12 are in Phase I, 39 are in Pre-clinical and ...

Dublin, March 28, 2017 (GLOBE NEWSWIRE) -- Research and Markets has announced the addition of the "Global Idiopathic Pulmonary Fibrosis (IPF) Pipeline Analysis, 2016" report to their offering. The IPF ...
technologynetworks

Towards a Gene Therapy for Reversal of Aging-Associated Pulmonary Fibrosis

The study, published in The Journal of Cell Biology, was conducted by CNIO researchers in collaboration with researchers from the Complutense University of Madrid and the Autonomous University of ...